GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3381)

  • GC69364 structure
    GC69364LDCA
    CAS: 349106-80-5
    Purity: >99.00%

    LDCA는 이중 대상 대사 조절제로, LDH-A 효소 활성을 억제하고 악성 종양군의 세포 사멸을 자극할 수 있습니다. LDCA는 암 진행 연구에 사용될 수 있습니다.

  • GC69379 structure
    GC69379Lipid 8
    CAS: 2226547-25-5
    Purity: >98.00%

    Lipid 8는 이온화 가능한 아미노 지질로, 지질 나노 입자 합성에 사용될 수 있습니다.

  • GC69380 structure
    GC69380Lirentelimab
    CAS: 2283348-97-8
    Purity: >98.00%

    Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding immunoglobulin-like lectin 8 (SIGLEC8). Lirentelimab induces apoptosis of IL-5 activated eosinophils and inhibits IL-5 mediated mast cell activation. Lirentelimab can be used for research on eosinophilic gastritis and duodenitis.

  • GC69405 structure
    GC69405L-Theanine-d5
    CAS: 1217451-85-8
    Purity: >99.00%

    L-Theanine-d5는 L-Theanine의 대위원소입니다. L-Theanine (L-Glutamic Acid γ-ethyl amide)은 녹차 잎에 존재하는 비단백질 아미노산물로, 뇌에서 글루타민과 글루타민 수용체 결합을 차단하여 신경 보호 및 항산화 활성을 가지고 있습니다. L-Theanine (L-Glutamic Acid γ-ethyl amide)을 경구 투여함으로써 대뇌 피질 신경세포의 자극 억제를 유도하여 항스트레스 작용을 나타낼 수 있습니다.

  • GC69444 structure
    GC69444MDM2-p53-IN-16
    CAS: 1917350-09-4
    Purity: >99.00%

    MDM2-p53-IN-16은 MDM2-p53 복합체 억제제로, 인간 MDM2-p532 복합체의 IC50 값이 4.3 nM입니다. MDM2-p53-IN-16은 p53을 재활성화시키며 다형성 신경교종 (GBM) 세포의 세포 사멸과 세포 주기 차단을 유도합니다. MDM2-p53-IN-16은 암 연구에 사용될 수 있습니다.

  • GC69590 structure
    GC69590Nrf2 activator-2
    CAS: 2770448-53-6
    Purity: >98.00%

    Nrf2 활성화제-2 (화합물 O15)는 뱀고사리 유래 물질로, 293 T 세포에서의 EC50 값은 2.9 μM입니다. Nrf2 활성화제-2는 Keap1과 Nrf2의 상호작용을 억제하여 Nrf2를 활성화시키는 효과가 있습니다. 또한, Nrf2 활성화제-2는 세포 내에서 유비쿼이틴화된 Nrf2 수준을 현저하게 감소시킵니다.

  • GC69648 structure
    GC69648p53 Activator 7
    CAS: 2849340-59-4
    Purity: >98.00%

    p53 Activator 7는 p53 돌연변이 Y220C (MDM-2/p53) 활성제로, EC50는 104 nM입니다. p53 Activator 7은 p53 돌연변이를 결합하여 DNA 결합 능력을 회복할 수 있습니다 (WO2022213975A1; 예시 B-1).

  • GC69673 structure
    GC69673PD-1/PD-L1-IN-13
    Purity: >98.00%

    PD-1/PD-L1-IN-13 (화합물 43)은 PD-1/PD-L1 면역 체크포인트 억제제로, PD-1/PD-L1 상호작용에 대한 IC50 값이 10.2 nM입니다. PD-1/PD-L1-IN-13은 Hepa1-6 동종 마우스 모델에서 CD8+ T 세포 활성을 촉진하고 종양 성장을 지연시킵니다.

  • GC69674 structure
    GC69674PD-1/PD-L1-IN-14
    CAS: 2499965-12-5
    Purity: >98.00%

    PD-1/PD-L1-IN-14 (화합물 17)은 PD-1/PD-L1 상호작용을 억제하는 약물로, 그 IC50 값은 27.8 nM입니다. PD-1/PD-L1-IN-14 (화합물 17)는 PD-1/PD-L1 상호작용을 억제하여 이중화를 촉진하고 내포 작용을 유도하며, PD-L1의 분해를 일으킵니다.

  • GC69675 structure
    GC69675PD1-PDL1-IN 1 TFA
    Purity: >95.00%

    PD1-PDL1-IN 1 TFA는 강력한 프로그램된 세포 사멸 1(PD-1) 억제제로 면역 조절제로 유용하다.

  • GC69676 structure
    GC69676PD-1/PD-L1-IN-29
    CAS: 2665734-13-2
    Purity: >98.00%

    PD-1/PD-L1-IN-29(S4-1)은 효과적인 PD-1/PD-L1 억제제로, 그 IC50 값은 6.1 nM입니다. PD-1/PD-L1-IN-29는 PD-L1에 결합하여 PD - 1/PD-L1 상호작용을 파괴하고, PD-L1 이중화 및 내부화를 유도하여 내피소망 위치를 개선하고, PD-L1의 소포체 진입을 촉진할 수 있습니다. 또한, PD- 11PD/LINN29는 항암 활성을 가지고 있습니다.

  • GC69677 structure
    GC69677MAX-10181
    CAS: 2171558-14-6
    Purity: >98.00%

    MAX-10181 (PD-1/PD-L1-IN-30)은 PD-1/PD-L1 결합 억제제로, IC50 값은 0.018 μM입니다. MAX-10181은 암 및 기타 관련 질환 연구에 사용될 수 있습니다.

  • GC69705 structure
    GC69705Physalin A
    CAS: 23027-91-0
    Purity: >98.00%

    Physalin A는 Physalis alkekengi var franchetii에서 분리된 withanolide입니다. Physalin A는 세포의 아포토시스 (apoptosis)를 유도하며 caspase-3 및 caspase-8 발현을 상승시킵니다. 또한, Physalin A는 자가포식을 유도하며 HT1080 세포의 아포토시스를 억제할 수 있다는 것이 발견되었습니다. 이러한 특성으로 인해 Physalin A는 암 연구에 대한 잠재력을 가지고 있습니다.

  • GC69795 structure
    GC69795(Rac)-BIO8898
    CAS: 402564-79-8
    Purity: >98.00%

    (Rac)-BIO8898는 CD40-CD154 공자극 상호작용 억제제입니다. (Rac)-BIO8898은 CD154과 CD40-Ig 결합을 억제하며, IC50 값은 25 μM입니다.

  • GC69801 structure
    GC69801Ragifilimab
    CAS: 2207590-51-8
    Purity: >95.00%

    Ragifilimab (INCAGN-1876) is a monoclonal antibody that targets glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for research on advanced or metastatic solid tumors.

  • GC69841 structure
    GC69841Rubropunctatin
    CAS: 514-67-0
    Purity: >98.00%

    Rubropunctatin은 홍흑균 발효 쌀(홍흑미) 추출물에서 분리된 주황색의 질소 잡초류 색소입니다. Rubropunctatin은 항염, 면역 억제 및 항산화 작용을 가지며 항암 활성도 있습니다.

  • GC69884 structure
    GC69884Shepherdin (79-87) (TFA)
    Purity: >98.00%

    Shepherdin (79-87) TFA는 Shepherdin의 79에서 87번 아미노산 단편입니다. Shepherdin은 Hsp90-Survivin 복합체의 펩타이드 대항제입니다. 항암 활성을 가지고 있습니다.

  • GC69899 structure
    GC69899SIRT6 activator 12q
    CAS: 2601734-99-8
    Purity: >98.00%

    SIRT6 activator 12q는 선택적 SIRT6 활성제 (IC 50 = 0.58 μM)이다.

  • GC69912 structure
    GC69912SLC7A11-IN-1
    Purity: >95.00%

    SLC7A11-IN-1은 효과적인 SLC7A11 억제제입니다. SLC7A11-IN-1은 성장 억제 활성을 나타냅니다. 또한, SLC7A11-IN-1은 세포 침습 및 전이를 억제합니다. SLC7A11-IN-1은 세포 사멸 (Apoptosis) 및 S 단계에서의 세포 주기 정지를 유도합니다. 따라서, SLC7A11-IN-1은 항암 활성을 가지고 있습니다.

  • GC69934 structure
    GC69934Spartalizumab
    CAS: 1935694-88-4
    Purity: >98.00%

    Spartalizumab (PDR001) is a humanized monoclonal antibody that binds to PD-1 with high affinity and blocks its interaction with PD-L1 and PD-L2. Spartalizumab is being studied for the treatment of anaplastic thyroid cancer (ATC).

  • GC69968 structure
    GC69968Sulanemadlin
    CAS: 1451199-98-6
    Purity: >96.50%

    Sulanemadlin은 막 투과성 있고 효과적인 대환 펩타이드 화합물 p53 대상을 바탕으로 안정적인 알파-나선펩타이드이다.

  • GC70026 structure
    GC70026Thymidine 3',5'-diphosphate tetrasodium
    CAS: 118675-87-9
    Purity: >97.00%

    티미딘 3',5'-이인산(Deoxythymidine 3',5'-diphosphate) 테트라소듐은 스태피로코커스 핵산효소와 1 Tudor 도메인(SND1, 마이크로RNA 조절 복합체 RISC 아기) 및 [3,5-2H2] 티로신 핵산효소([3,5-2H2] tyrosyl nuclease)의 선택적 억제제입니다. Thymidine 3',5'-diphosphate tetrasodium은 항암 활성을 가지며 생화학 반응에서도 촉매로 사용될 수 있습니다.

  • GC70039 structure
    GC70039TNF-α (46-65), human TFA
    Purity: >98.00%

    TNF-α (46-65), human (TFA)는 인간 TNF-α의 다중 펩타이드 조각입니다.

  • GC70104 structure
    GC70104Utomilumab
    CAS: 1417318-27-4
    Purity: >99.00%

    Utomilumab (PF 05082566)은 인간 유래의 IgG2 mAb 활성제로, T 세포 공동 자극 수용체 4-1BB/CD137을 타겟으로 합니다. Utomilumab은 재발/치료 어려운 만성림프구종 (FL) 및 기타 CD20+ 비호지킨 림프종(NHL) 연구에 사용될 수 있습니다.